The Pharmacy Times® Ovarian Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to the group of diseases that originates in the ovaries, fallopian tubes, or the peritoneum.
March 31st 2023
Experts note that pharmacists are well positioned to play a key role in precision oncology and molecular tumor boards.
FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx for Platinum-Resistant Ovarian Cancer TreatmentNovember 15th 2022
Mirvetuximab soravtansine-gynx (Elahere; ImmunoGen Inc) approved FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
FDA Approves Bevacizumab Biosimilar for Six Types of CancerSeptember 28th 2022
Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Clovis Oncology Submits New Drug Application for Rucaparib as First-Line Maintenance Treatment for Advanced Ovarian CancerSeptember 14th 2022
Research suggests that rucaparib can increase progression-free survival by more than a year in women with advanced ovarian cancer.
Study: Rucaparib Improves Progression-Free Survival as First-Line Maintenance Therapy in Advanced Ovarian CancerSeptember 12th 2022
New results presented at the 2022 ESMO conference reinforce the potential of rucaparib as a first-line maintenance treatment option in a broad population of patients with ovarian cancer.
Study Finds Genetic Counseling for Breast, Ovarian Cancer Syndrome Did Not Significantly Increase with Clinician SupportAugust 15th 2022
Women at high risk for breast and ovarian cancer felt less worried and better informed with educational intervention, even if their attendance of genetic counseling did not significantly increase.
FDA Approves Dabrafenib Plus Trametinib for Unresectable, Metastatic Solid Tumors With BRAF V600E MutationJune 23rd 2022
In clinical trials, dabrafenib and trametinib showed meaningful efficacy in multiple BRAF-positive tumor types, including in patients with rare cancers who have no other treatment options available.
Safety Data Supports Rucaparib With Nivolumab, Ipilimumab Moving to Phase 2 Trial for Replaced Ovarian CancerJune 6th 2022
Rucaparib at the 400 mg dosage combined with nivolumab and ipilimumab for 4 cycles will continue onto a phase 2 trial for individuals with relapsed ovarian cancer.
PARPi Use Associated With Significantly Improved Progression-Free Survival in Patients with Newly Diagnosed Advanced Ovarian CancerJune 6th 2022
The researchers noted that the objective of the study was to assess the trends of 1L PARPi maintenance treatment uptake and PFS of patients with newly diagnosed AOC.
Rucaparib Shows Efficacy Across Tumors Associated With Different Genetic AlterationsApril 11th 2022
Poster at AACR highlights in vitro and in vivosynthetic lethality activity of rucaparib in multiple cancer cell types and PDX tumors that harbor genetic or epigenetic alterations in non-BRCA HRR genes.
BLA Submitted for Mirvetuximab Soravtansine in Ovarian CancerMarch 30th 2022
ImmunoGen, Inc submits Biologics License Application under the accelerated approval pathway for mirvetuximab soravtansine monotherapy for patients with FRα-high platinum-resistant ovarian cancer previously treated with 1 to 3 prior systemic treatments.
Clincial Trials Show Niraparib Improves PFS With Tolerable Safety Profile Following Response to Platinum-based Chemotherapy in Ovarian CancerMarch 22nd 2022
Niraparib shows promise in patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
PARP Inhibitors Play Important Role in Frontline, Recurrent Maintenance Treatment of Ovarian CancerMarch 21st 2022
Growing evidence indicates that PARP inhibition, both as frontline maintenance and recurrent maintenance, is important for many patients with ovarian cancer.